New asthma drug aims to stop attacks in severe cases

NCT ID NCT07098403

Recruiting now Disease control Sponsor: Guangdong Hengrui Pharmaceutical Co., Ltd Source: ClinicalTrials.gov ↗

First seen Jun 25, 2026 · Last updated Jun 26, 2026 · Updated 1 time

Summary

This phase 3 trial tests a new drug called SHR-1905 for adults with severe asthma that is not well controlled by current treatments. The study will compare the drug to a placebo to see if it reduces asthma attacks and improves lung function. About 408 participants will take part across multiple centers.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: SHR-1905 injection
What this could lead to: If successful, this could provide a new treatment option to reduce asthma attacks and improve breathing for people with severe uncontrolled asthma.
What could go wrong: This is a phase 3 trial, but results are not yet known. The drug may not work better than placebo, and side effects are possible. It is not a cure.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ASTHMA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

asthma chronic asthma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

ASTHMA

Contacts and locations

Locations

The First Affiliated Hospital of Guangzhou Medical University
RECRUITING

Guangzhou, Guangdong, 510830, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.